Moderna Brings More Melanoma Trial Data to ESMO Congress
Moderna will present additional melanoma trial data at the ESMO Congress, and retail analysts say the breakout is getting hard to ignore.
Topic
Mrna Therapeutics
Topic
Mrna Therapeutics
Moderna Stock Jumps 9% on Phase 3 Melanoma Slot at Symposium
Moderna stock surged 9% after its Phase 3 melanoma data earned a Presidential Symposium slot, lifting Merck and BioNTech; full en…